The Lancet Oncology最新文献

{"title":"De-escalated adjuvant radiotherapy versus standard adjuvant treatment for human papillomavirus-associated oropharyngeal squamous cell carcinoma (MC1675): a phase 3, open-label, randomised controlled trial","authors":"Daniel Ma, Katharine Price, Eric Moore, Samir Patel, Michael Hinni, David Routman, Briant Fruth, Nathan Foster, Kathryn Van Abel, Linda Yin, Michelle Neben-Wittich, Yolanda Garces, Lisa McGee, Scott Lester, Jean-Claude Rwigema, Adam Holtzman, Daniel Price, Jeffrey Janus, Jan Kasperbauer, Ashish Chintakuntlawar, Robert Foote","doi":"10.1016/s1470-2045(25)00324-9","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00324-9","url":null,"abstract":"<h3>Background</h3>Standard adjuvant chemoradiotherapy (60–66 Gy) following surgery for HPV-associated oropharyngeal squamous cell carcinoma has excellent oncological control but high treatment morbidity. We aimed to compare toxicity of a 30–36 Gy regimen of de-escalated adjuvant radiotherapy and standard of care treatment.<h3>Methods</h3>We did this phase 3, open-label, randomised controlled trial in two academic sites in the USA. Eligible participants were adults aged 18 years or older, with American Joint Committee on Cancer 7th edition pathological stage III–IV HPV-associated oropharyngeal squamous cell carcinoma and had more than 70% p16-immunoreactivity on immunohistochemistry evaluation of the surgical specimen. All patients had an Eastern Cooperative Oncology Group (ECOG) performance status of 1 or less and at least one intermediate pathological risk factor. Patients were stratified by the presence of extranodal extension and smoking status (<10 packs per year <em>vs</em> ≥10 packs per year) Eligible patients were randomly assigned (2:1) using a minimisation method with a random element to receive de-escalated adjuvant radiotherapy (30–36 Gy in 1·5–1·8 Gy fractions twice per day over 2 weeks plus intravenous docetaxel 15 mg/m<sup>2</sup> on days 1 and 8 of treatment) or standard of care (60 Gy in 2 Gy fractions once daily over 6 weeks plus intravenous cisplatin 40 mg/m<sup>2</sup> once a week). The primary endpoint was cumulative, chronic grade 3 or higher toxicity rate 3–24 months after radiotherapy. Primary analysis was done in patients who received treatment and had no missing data. This trial is registered with <span><span>ClinicalTrials.gov</span><svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"><path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"></path></svg></span>, <span><span>NCT02908477</span><svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"><path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"></path></svg></span>, and is complete.<h3>Findings</h3>Between Oct 11, 2016, and Aug 20, 2020, 254 patients with newly diagnosed oropharyngeal squamous cell carcinoma were assessed for inclusion. Nine did not meet inclusion criteria and 17 declined to participate. 228 patients were enrolled, with 194 proceeding to protocol treatment and analysis (130 in the de-escalated adjuvant radiotherapy group and 64 in the standard of care group). Median patient age was 59·4 years (range 37·9–81·6). 173 (89%) of 194 patients were male and 21 (11%) were female. 183 (95%) of 194 patients were White, four (2%) were Hispanic, three (2%) were Asian, and one (1%) was Native American. Median follow-up was 37·3 months (IQR 27·6–49·2). Seven patients were excluded from analysis of the primary late toxicity endpoint (five patients in the de-escalated adjuvant radiotherapy group and two patients i","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"52 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144927897","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Public and philanthropic research funding, publications, and research networks for cancer in the Commonwealth and globally between 2016 and 2023: a comparative analysis","authors":"Anbang Du, Markus Brede, Stuart A McIntosh, Beining Zhang, Aminu O Alem, Gabriela Borin, Wilson Cheah, Ellen Copson, Ramsey I Cutress, Anna Folz, Emily T Helms, Zain Memon, Olabiyi H Olaniran, Constantinos Savva, Edward Thomas, Rifat Atun, Michael G Head","doi":"10.1016/s1470-2045(25)00338-9","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00338-9","url":null,"abstract":"This Review presents a comprehensive analysis of the amounts and distribution of public and philanthropic global cancer research funding between 2016 and 2023, including patterns of international collaboration and downstream research output, with an emphasis on the Commonwealth. We show that annual investment decreased globally each year, apart from a rise in 2021. Network analysis revealed that grant and publication collaborations between the Commonwealth, the USA, and the EU are facilitated by linkages through a core group of Commonwealth countries, including the UK, Australia, and Canada. There are inequities in research investment and low funding for treatment modalities for many cancers. These inequities also manifest in the central positioning of high-income Commonwealth countries in research collaborations, but also point to opportunities for high-income Commonwealth countries to facilitate linkages with low-income countries and support active cancer research in the USA and the EU. There is an urgent need to review research investment priorities, both within the Commonwealth and globally, to align with population needs and promote collaborative strategies that can build research skills and infrastructure in low-income settings to impact global cancer control. Finite resources should be invested wisely to achieve maximum improvements in mortality and alleviate the cancer burden.","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"60 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144927898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Importance of responder criteria for reporting health-related quality-of-life data in clinical trials for advanced cancer: recommendations of Common Sense Oncology and the European Organisation for Research and Treatment of Cancer","authors":"Ian F Tannock, Madeline Lee Pe, Christopher M Booth, Michael Brundage, Nathan I Cherny, Corneel Coens, Elizabeth A Eisenhauer, Jan Geissler, Johannes M Giesinger, Bishal Gyawali, Sjoukje F Oosting, Gregory R Pond, Jaap C Reijneveld, Enrique Soto-Perez-de-Celis, Michelle Tregear, Winette T A van der Graaf","doi":"10.1016/s1470-2045(25)00288-8","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00288-8","url":null,"abstract":"The goals of treatment for people with advanced cancer are to prolong survival and improve symptoms and health-related quality of life (HRQOL). Although many phase 3 randomised clinical trials seek to evaluate HRQOL during treatment, informing individual patients about expected HRQOL outcomes is challenging, as the common method of analysis and reporting compares averages for randomised groups, and clinicians find these data difficult to apply in clinical practice. Symptomatic patients with advanced cancer would like to know the probability that a proposed treatment might improve their survival or their dominant symptoms, and the probability of having treatment-related side-effects. When specifying HRQOL endpoints, we recommend that trialists develop HRQOL hypotheses about which dominant symptoms might be improved due to the initiation of the investigational treatment, and whether aspects of functioning and overall HRQOL will also improve despite the side-effects of the treatment. Validated, disease-specific, patient-reported outcome measures should be used to assess the relevant HRQOL concepts. Changes in HRQOL should be reported as the proportion of patients who have a specified improvement (or deterioration) in these relevant HRQOL scales (ie, as a response criterion), and harmonised standards for such a response criterion are needed.","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"13 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144927901","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metastases-directed therapy in addition to standard systemic therapy in oligometastatic castration-resistant prostate cancer in Canada (GROUQ-PCS 9): a multicentre, open-label, randomised, phase 2 trial","authors":"Tamim Niazi, Fred Saad, Steven Tisseverasinghe, Rashmi Koul, Isabelle Thibault, Peter W M Chung, George Wakil, Michael Lock, Guila Delouya, Boris Bahoric, Andrew Feifer, Venkata Ramana Agnihotram, Theodoros Tsakiridis, Fabio L Cury, Rafika Dahmane, Nikhilesh Gajanan Patil, Scott Tyldesley","doi":"10.1016/s1470-2045(25)00351-1","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00351-1","url":null,"abstract":"<h3>Background</h3>The role of metastasis-directed therapy (MDT) in castration-resistant prostate cancer (CRPC) remains unclear. Prostate Cancer Study 9 (PCS-9) aimed to evaluate the benefits of stereotactic body radiotherapy (SBRT) in addition to standard systemic therapy in patients with oligometastatic CRPC.<h3>Methods</h3>This open-label, randomised, phase 2 trial was conducted across 13 Canadian academic and community oncology centres. Male patients aged 18 years or older, with an Eastern Cooperative Oncology Group performance status of 0–2, and histologically confirmed oligometastatic CRPC (≤5 metastases), who had progressed on androgen deprivation therapy (ADT), were randomly assigned (1:1) to ADT–enzalutamide (ENZA; 160 mg once daily) or ADT–ENZA–SBRT to all oligometastatic sites. Randomisation was completed by sequentially numbered, sealed opaque envelopes, and stratified by the location of the metastasis. The primary endpoint was radiographic progression-free survival. Analysis was performed on an intention-to-treat basis. This study is registered with <span><span>ClinicalTrials.gov</span><svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"><path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"></path></svg></span>, <span><span>NCT02685397</span><svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"><path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"></path></svg></span>, and was halted and completed at the phase 2 stage.<h3>Findings</h3>Between Oct 18, 2016, and July 31, 2023, 102 male patients were randomly assigned to ADT–ENZA (n=49) or ADT–ENZA–SBRT (n=53); after excluding one patient per treatment group due to early withdrawal and insufficient data, 48 patients in the ADT–ENZA group and 52 patients in the ADT–ENZA–SBRT group were included in the final analysis. Most patients were White (80 [80%]) and median age was 73·0 years (IQR 67·0–79·5). At a median follow-up of 4·8 years (IQR 3·4–5·0), ADT–ENZA–SBRT significantly improved radiographic progression-free survival compared with ADT–ENZA alone (median radiographic progression-free survival, 4·6 years [95% CI 3·7–not reached] <em>vs</em> 2·3 years [1·4–3·7]; hazard ratio 0·48 [95% CI 0·27–0·86]; p=0·014). The most common grade 3 treatment related adverse event was impotence (eight [57%] of 14 patients in the ADT–ENZA group and nine [75%] of 12 patients in the ADT–ENZA–SBRT group). There were no grade 4 toxicities and no treatment-related deaths.<h3>Interpretation</h3>These results demonstrate that SBRT, when combined with ADT–ENZA, prolongs disease control in oligometastatic CRPC by doubling median radiographic progression-free survival, with similar toxicity profiles between the groups. These findings support integrating SBRT into the treatment paradigm for oligometastatic CRPC.<h3>Funding</h3>Jewish General Hospital (Astellas C","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"31 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144928548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clarifying the consensus on laryngeal preservation strategies – Authors' reply","authors":"Marco Ferrari, Francesca Mularoni, Davide Smussi, Piergiorgio Gaudioso, Pierluigi Bonomo, Jeppe Friborg, Maria Grazia Ghi, Vincent Gregoire, Kevin Harrington, Keith Hunter, Roberto Maroldi, Rosemary Martino, Ricard Mesia, Giorgio Peretti, Amanda Psyrri, Antonio Schindler, Giovanni Succo, Petr Szturz, Isabel Vilaseca, Piero Nicolai, Paolo Bossi","doi":"10.1016/s1470-2045(25)00467-x","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00467-x","url":null,"abstract":"No Abstract","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"28 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144927841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lenvatinib plus pembrolizumab in pretreated metastatic B3 thymoma and thymic carcinoma (PECATI): a single-arm, phase 2 trial","authors":"Jordi Remon, Paolo Bironzo, Nicolas Girard, Laurence Bigay-Game, Oscar Juan-Vidal, Javier de Castro, Noemí Reguart, Laurent Greillier, Sophie Cousin, Eric Dansin, Margarita Majem, Reyes Bernabé, Joaquin Mosquera Martinez, Marta Díaz, Alba Meya, Daniel Alcalá-López, Alicia García-Sanz, Luisella Righi, Silvia Novello, Benjamin Besse","doi":"10.1016/s1470-2045(25)00300-6","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00300-6","url":null,"abstract":"<h3>Background</h3>No standard treatment exists for patients with platinum-refractory advanced type B3 thymoma and thymic carcinoma. In the PECATI trial, we sought to assess the antitumour activity and safety of lenvatinib plus pembrolizumab in this population.<h3>Methods</h3>In this single-arm phase 2 trial, we recruited participants from 11 hospitals in France, Italy, and Spain. Eligible participants were adults (aged ≥18 years), with an Eastern Cooperative Oncology Group performance status of 0–1, and with relapsed or recurrent histologically confirmed type B3 thymoma or thymic carcinoma, at a metastatic stage of disease, who had received at least one line of platinum-based chemotherapy and had progressed during or after the previous line of chemotherapy, and did not have an autoimmune disorder. Participants received lenvatinib (20 mg orally once a day) combined with pembrolizumab (200 mg intravenously, infused over 30 min on day one of each cycle) in 3-week cycles for a maximum of 35 cycles (2 years), with treatment discontinued for reasons including confirmed clinical or radiological disease progression or unacceptable toxicity. The primary endpoint was 5-month progression-free survival (null hypothesis: 5-month progression-free survival of ≤50%; alternative hypothesis: 5-month progression-free survival of ≥68·6%) assessed by the investigators in the full analysis set. Safety was assessed in all participants who received at least one dose of study treatment. The data cutoff date for the current analyses was July 1, 2024. The trial was registered on <span><span>ClinicalTrials.gov</span><svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"><path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"></path></svg></span>, <span><span>NCT04710628</span><svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"><path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"></path></svg></span>, and is ongoing.<h3>Findings</h3>From May 13, 2022, to Feb 1, 2024, 43 participants were enrolled and started study treatment (18 [42%] female and 25 [58%] male; 27 [63%] White, four [9%] Arabic or North African, one [2%] Albanian, one [2%] Black, and ten [23%] ethnicity missing). Median age was 57 years (IQR 45–66). 36 (84%) participants had thymic carcinoma and seven (16%) had B3 thymoma. Masaoka–Koga stage IVA disease was recorded in 15 (35%) participants and stage IVB in 28 (65%), including 16 (37%) participants with liver metastases. 23 (53%) participants had three or more metastatic sites. 20 (47%) participants had received two or more previous lines of therapy. After a median follow-up of 10·6 months (IQR 7·8–14·7), the study met its primary endpoint, with 5-month progression-free survival of 88·4% (90% CI 79·8–96·7). Treatment-emergent adverse events were reported in 42 (98%) of 43 participants, the most common being h","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144927896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to Lancet Oncol 2025; 26: 1113–22","authors":"","doi":"10.1016/s1470-2045(25)00477-2","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00477-2","url":null,"abstract":"<em>Ho AS, Huang SH, O’Sullivan B, et al. Derivation and validation of the AJCC9V pathological stage classification for HPV-positive oropharyngeal carcinoma: a multicentre registry analysis.</em> Lancet Oncol <em>2025; <strong>26:</strong> 1113–22</em>—In this Article, the red and green curves in figure 2B, corresponding to N2 and N3, have been updated. This correction has been made to the online version as of Sept 1, 2025.","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"71 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144927844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Refining risk stratification in meningiomas: beyond TERT promoter mutations","authors":"Gianluca Scalia","doi":"10.1016/s1470-2045(25)00476-0","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00476-0","url":null,"abstract":"No Abstract","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"8 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144927837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"De-escalation of adjuvant radiotherapy in HPV-associated oropharyngeal cancer","authors":"Imran Petkar","doi":"10.1016/s1470-2045(25)00408-5","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00408-5","url":null,"abstract":"No Abstract","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"31 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144927839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Establishing the China–UK Cancer Prevention and Control Alliance","authors":"Jun Ma, David Kerr, Yuankai Shi, Charles Swanton, Tony Mok, Rebecca Fitzgerald, Rui-Hua Xu, Richard Cowan, Rong Lin, Mark Lawler, Gao-Jun Teng, Tim Eisen, Molly Li, Maria Kyrgiou, Fanny Wai San Ko, Mark Middleton, Binghe Xu, Eric Aboyage, Dan Xiao, Yi-Long Wu, Daiming Fan","doi":"10.1016/s1470-2045(25)00437-1","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00437-1","url":null,"abstract":"No Abstract","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"25 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144927840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}